Loading…
Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor
BACKGROUND: A combination of chemotherapy plus granulocyte–colony‐stimulating factor (G‐CSF) (chemomobilization) is commonly used to mobilize CD34+ cells to circulation. Plerixafor, a chemokine CXCR4 antagonist, increases the mobilization of CD34+ cells and may also have effect on graft composition....
Saved in:
Published in: | Transfusion (Philadelphia, Pa.) Pa.), 2012-08, Vol.52 (8), p.1785-1791 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4705-33a115d1a505dbccbb750df610cf633dc4c74c55a3575386999a6e78fce277123 |
---|---|
cites | cdi_FETCH-LOGICAL-c4705-33a115d1a505dbccbb750df610cf633dc4c74c55a3575386999a6e78fce277123 |
container_end_page | 1791 |
container_issue | 8 |
container_start_page | 1785 |
container_title | Transfusion (Philadelphia, Pa.) |
container_volume | 52 |
creator | Varmavuo, Ville Mäntymaa, Pentti Kuittinen, Taru Nousiainen, Tapio Jantunen, Esa |
description | BACKGROUND: A combination of chemotherapy plus granulocyte–colony‐stimulating factor (G‐CSF) (chemomobilization) is commonly used to mobilize CD34+ cells to circulation. Plerixafor, a chemokine CXCR4 antagonist, increases the mobilization of CD34+ cells and may also have effect on graft composition.
STUDY DESIGN AND METHODS: We have analyzed lymphocyte subsets in grafts collected on the next morning after plerixafor injection in 13 chemomobilized patients with non‐Hodgkin's lymphoma (NHL) mobilizing poorly. As controls we had the first leukapheresis products from 11 NHL patients mobilized with chemotherapy plus G‐CSF. The analyses were performed from cryopreserved apheresis products.
RESULTS: The median counts of both total CD3+ T cells and natural killer (NK) cells (CD3–CD16/56+) in the graft were significantly higher in plerixafor‐treated group compared to the control group. Both helper T‐lymphocytes (CD3+CD4+) and suppressor T‐lymphocytes (CD3+CD8+) were significantly increased in the plerixafor‐treated group so that CD4+/CD8+ ratio in the graft did not differ between the groups. CD19+ cells were evident only at very small amounts in few patients in both groups, and the CD34+ cell content of the graft did not differ between the groups. Engraftment after high‐dose therapy was comparable between the groups.
CONCLUSION: Plerixafor added to chemomobilization in poor mobilizers seems to mobilize more T cells and NK cells than chemomobilization. Larger patient numbers and longer follow‐up is needed in regard to evaluate posttransplant complications and risk of relapse in patients receiving plerixafor due to poor mobilization. |
doi_str_mv | 10.1111/j.1537-2995.2011.03525.x |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1464498669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1464498669</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4705-33a115d1a505dbccbb750df610cf633dc4c74c55a3575386999a6e78fce277123</originalsourceid><addsrcrecordid>eNqNkU9v0zAYhyMEYmXwFZAvCC4p_hPbyYEDVGwFTSChIbhZjuO07pw4sx2t2Vfal8RZS7nii1_Zz_O-ln9ZBhBcorTe75aIEp7jqqJLDBFaQkIxXe6fZIvTxdNsAWGBcoQIPstehLCDEOIKoufZGcYEFkWBF9nDJ-tcAzZethHYqRu2Tk1RgzDWQccA0rH2YLDam71snQem32kVjetTBXrX52vXbG5M_zYc9U6CQUaj-2R3rjbW3Jt-AwbnvJ3AnYlboLa6c3GrvRym1HsM8_x-tI-jc-Ws66c8RNONNnVKcitVdP5l9qyVNuhXx_08-3nx-Xq1zq--X35ZfbzKVcEhzQmRCNEGSQppUytV15zCpmUIqpYR0qhC8UJRKgnllJSsqirJNC9bpTHnCJPz7N2h7-Dd7ahDFJ0JSlsre-3GIFDBiqIqGasSWh5Q5V0IXrdi8KaTfhIIijkqsRNzImJORMxRiceoxD6pr49TxrrTzUn8m00C3hwBGZS0bfoiZcI_juGScQYT9-HA3Rmrp_9-gLj-cTFXyc8PvglR70--9DeCccKp-PXtUiC8_lry36tk_wFDt8OL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1464498669</pqid></control><display><type>article</type><title>Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor</title><source>Wiley</source><creator>Varmavuo, Ville ; Mäntymaa, Pentti ; Kuittinen, Taru ; Nousiainen, Tapio ; Jantunen, Esa</creator><creatorcontrib>Varmavuo, Ville ; Mäntymaa, Pentti ; Kuittinen, Taru ; Nousiainen, Tapio ; Jantunen, Esa</creatorcontrib><description>BACKGROUND: A combination of chemotherapy plus granulocyte–colony‐stimulating factor (G‐CSF) (chemomobilization) is commonly used to mobilize CD34+ cells to circulation. Plerixafor, a chemokine CXCR4 antagonist, increases the mobilization of CD34+ cells and may also have effect on graft composition.
STUDY DESIGN AND METHODS: We have analyzed lymphocyte subsets in grafts collected on the next morning after plerixafor injection in 13 chemomobilized patients with non‐Hodgkin's lymphoma (NHL) mobilizing poorly. As controls we had the first leukapheresis products from 11 NHL patients mobilized with chemotherapy plus G‐CSF. The analyses were performed from cryopreserved apheresis products.
RESULTS: The median counts of both total CD3+ T cells and natural killer (NK) cells (CD3–CD16/56+) in the graft were significantly higher in plerixafor‐treated group compared to the control group. Both helper T‐lymphocytes (CD3+CD4+) and suppressor T‐lymphocytes (CD3+CD8+) were significantly increased in the plerixafor‐treated group so that CD4+/CD8+ ratio in the graft did not differ between the groups. CD19+ cells were evident only at very small amounts in few patients in both groups, and the CD34+ cell content of the graft did not differ between the groups. Engraftment after high‐dose therapy was comparable between the groups.
CONCLUSION: Plerixafor added to chemomobilization in poor mobilizers seems to mobilize more T cells and NK cells than chemomobilization. Larger patient numbers and longer follow‐up is needed in regard to evaluate posttransplant complications and risk of relapse in patients receiving plerixafor due to poor mobilization.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/j.1537-2995.2011.03525.x</identifier><identifier>PMID: 22304442</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject><![CDATA[Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antibodies, Monoclonal, Murine-Derived - administration & dosage ; Antigens, CD34 - metabolism ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Apheresis ; Biological and medical sciences ; Blood Component Removal - methods ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Combined Modality Therapy ; Cyclophosphamide - administration & dosage ; Doxorubicin - administration & dosage ; Female ; Follow-Up Studies ; Granulocyte Colony-Stimulating Factor - administration & dosage ; Hematopoietic Stem Cell Mobilization - methods ; Hematopoietic Stem Cells - cytology ; Hematopoietic Stem Cells - metabolism ; Heterocyclic Compounds - administration & dosage ; Humans ; Leukocyte Count ; Lymphocyte Subsets - cytology ; Lymphoma, Non-Hodgkin - drug therapy ; Lymphoma, Non-Hodgkin - immunology ; Male ; Medical sciences ; Middle Aged ; Prednisone - administration & dosage ; Receptors, CXCR4 - antagonists & inhibitors ; Retrospective Studies ; Rituximab ; Stem Cell Transplantation ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation, Autologous ; Vincristine - administration & dosage]]></subject><ispartof>Transfusion (Philadelphia, Pa.), 2012-08, Vol.52 (8), p.1785-1791</ispartof><rights>2012 American Association of Blood Banks</rights><rights>2015 INIST-CNRS</rights><rights>2012 American Association of Blood Banks.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4705-33a115d1a505dbccbb750df610cf633dc4c74c55a3575386999a6e78fce277123</citedby><cites>FETCH-LOGICAL-c4705-33a115d1a505dbccbb750df610cf633dc4c74c55a3575386999a6e78fce277123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26286760$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22304442$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Varmavuo, Ville</creatorcontrib><creatorcontrib>Mäntymaa, Pentti</creatorcontrib><creatorcontrib>Kuittinen, Taru</creatorcontrib><creatorcontrib>Nousiainen, Tapio</creatorcontrib><creatorcontrib>Jantunen, Esa</creatorcontrib><title>Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>BACKGROUND: A combination of chemotherapy plus granulocyte–colony‐stimulating factor (G‐CSF) (chemomobilization) is commonly used to mobilize CD34+ cells to circulation. Plerixafor, a chemokine CXCR4 antagonist, increases the mobilization of CD34+ cells and may also have effect on graft composition.
STUDY DESIGN AND METHODS: We have analyzed lymphocyte subsets in grafts collected on the next morning after plerixafor injection in 13 chemomobilized patients with non‐Hodgkin's lymphoma (NHL) mobilizing poorly. As controls we had the first leukapheresis products from 11 NHL patients mobilized with chemotherapy plus G‐CSF. The analyses were performed from cryopreserved apheresis products.
RESULTS: The median counts of both total CD3+ T cells and natural killer (NK) cells (CD3–CD16/56+) in the graft were significantly higher in plerixafor‐treated group compared to the control group. Both helper T‐lymphocytes (CD3+CD4+) and suppressor T‐lymphocytes (CD3+CD8+) were significantly increased in the plerixafor‐treated group so that CD4+/CD8+ ratio in the graft did not differ between the groups. CD19+ cells were evident only at very small amounts in few patients in both groups, and the CD34+ cell content of the graft did not differ between the groups. Engraftment after high‐dose therapy was comparable between the groups.
CONCLUSION: Plerixafor added to chemomobilization in poor mobilizers seems to mobilize more T cells and NK cells than chemomobilization. Larger patient numbers and longer follow‐up is needed in regard to evaluate posttransplant complications and risk of relapse in patients receiving plerixafor due to poor mobilization.</description><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antibodies, Monoclonal, Murine-Derived - administration & dosage</subject><subject>Antigens, CD34 - metabolism</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Apheresis</subject><subject>Biological and medical sciences</subject><subject>Blood Component Removal - methods</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Combined Modality Therapy</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Granulocyte Colony-Stimulating Factor - administration & dosage</subject><subject>Hematopoietic Stem Cell Mobilization - methods</subject><subject>Hematopoietic Stem Cells - cytology</subject><subject>Hematopoietic Stem Cells - metabolism</subject><subject>Heterocyclic Compounds - administration & dosage</subject><subject>Humans</subject><subject>Leukocyte Count</subject><subject>Lymphocyte Subsets - cytology</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Lymphoma, Non-Hodgkin - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prednisone - administration & dosage</subject><subject>Receptors, CXCR4 - antagonists & inhibitors</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Stem Cell Transplantation</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation, Autologous</subject><subject>Vincristine - administration & dosage</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqNkU9v0zAYhyMEYmXwFZAvCC4p_hPbyYEDVGwFTSChIbhZjuO07pw4sx2t2Vfal8RZS7nii1_Zz_O-ln9ZBhBcorTe75aIEp7jqqJLDBFaQkIxXe6fZIvTxdNsAWGBcoQIPstehLCDEOIKoufZGcYEFkWBF9nDJ-tcAzZethHYqRu2Tk1RgzDWQccA0rH2YLDam71snQem32kVjetTBXrX52vXbG5M_zYc9U6CQUaj-2R3rjbW3Jt-AwbnvJ3AnYlboLa6c3GrvRym1HsM8_x-tI-jc-Ws66c8RNONNnVKcitVdP5l9qyVNuhXx_08-3nx-Xq1zq--X35ZfbzKVcEhzQmRCNEGSQppUytV15zCpmUIqpYR0qhC8UJRKgnllJSsqirJNC9bpTHnCJPz7N2h7-Dd7ahDFJ0JSlsre-3GIFDBiqIqGasSWh5Q5V0IXrdi8KaTfhIIijkqsRNzImJORMxRiceoxD6pr49TxrrTzUn8m00C3hwBGZS0bfoiZcI_juGScQYT9-HA3Rmrp_9-gLj-cTFXyc8PvglR70--9DeCccKp-PXtUiC8_lry36tk_wFDt8OL</recordid><startdate>201208</startdate><enddate>201208</enddate><creator>Varmavuo, Ville</creator><creator>Mäntymaa, Pentti</creator><creator>Kuittinen, Taru</creator><creator>Nousiainen, Tapio</creator><creator>Jantunen, Esa</creator><general>Blackwell Publishing Inc</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201208</creationdate><title>Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor</title><author>Varmavuo, Ville ; Mäntymaa, Pentti ; Kuittinen, Taru ; Nousiainen, Tapio ; Jantunen, Esa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4705-33a115d1a505dbccbb750df610cf633dc4c74c55a3575386999a6e78fce277123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antibodies, Monoclonal, Murine-Derived - administration & dosage</topic><topic>Antigens, CD34 - metabolism</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Apheresis</topic><topic>Biological and medical sciences</topic><topic>Blood Component Removal - methods</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Combined Modality Therapy</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Granulocyte Colony-Stimulating Factor - administration & dosage</topic><topic>Hematopoietic Stem Cell Mobilization - methods</topic><topic>Hematopoietic Stem Cells - cytology</topic><topic>Hematopoietic Stem Cells - metabolism</topic><topic>Heterocyclic Compounds - administration & dosage</topic><topic>Humans</topic><topic>Leukocyte Count</topic><topic>Lymphocyte Subsets - cytology</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Lymphoma, Non-Hodgkin - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prednisone - administration & dosage</topic><topic>Receptors, CXCR4 - antagonists & inhibitors</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Stem Cell Transplantation</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation, Autologous</topic><topic>Vincristine - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Varmavuo, Ville</creatorcontrib><creatorcontrib>Mäntymaa, Pentti</creatorcontrib><creatorcontrib>Kuittinen, Taru</creatorcontrib><creatorcontrib>Nousiainen, Tapio</creatorcontrib><creatorcontrib>Jantunen, Esa</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Varmavuo, Ville</au><au>Mäntymaa, Pentti</au><au>Kuittinen, Taru</au><au>Nousiainen, Tapio</au><au>Jantunen, Esa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2012-08</date><risdate>2012</risdate><volume>52</volume><issue>8</issue><spage>1785</spage><epage>1791</epage><pages>1785-1791</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>BACKGROUND: A combination of chemotherapy plus granulocyte–colony‐stimulating factor (G‐CSF) (chemomobilization) is commonly used to mobilize CD34+ cells to circulation. Plerixafor, a chemokine CXCR4 antagonist, increases the mobilization of CD34+ cells and may also have effect on graft composition.
STUDY DESIGN AND METHODS: We have analyzed lymphocyte subsets in grafts collected on the next morning after plerixafor injection in 13 chemomobilized patients with non‐Hodgkin's lymphoma (NHL) mobilizing poorly. As controls we had the first leukapheresis products from 11 NHL patients mobilized with chemotherapy plus G‐CSF. The analyses were performed from cryopreserved apheresis products.
RESULTS: The median counts of both total CD3+ T cells and natural killer (NK) cells (CD3–CD16/56+) in the graft were significantly higher in plerixafor‐treated group compared to the control group. Both helper T‐lymphocytes (CD3+CD4+) and suppressor T‐lymphocytes (CD3+CD8+) were significantly increased in the plerixafor‐treated group so that CD4+/CD8+ ratio in the graft did not differ between the groups. CD19+ cells were evident only at very small amounts in few patients in both groups, and the CD34+ cell content of the graft did not differ between the groups. Engraftment after high‐dose therapy was comparable between the groups.
CONCLUSION: Plerixafor added to chemomobilization in poor mobilizers seems to mobilize more T cells and NK cells than chemomobilization. Larger patient numbers and longer follow‐up is needed in regard to evaluate posttransplant complications and risk of relapse in patients receiving plerixafor due to poor mobilization.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>22304442</pmid><doi>10.1111/j.1537-2995.2011.03525.x</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1132 |
ispartof | Transfusion (Philadelphia, Pa.), 2012-08, Vol.52 (8), p.1785-1791 |
issn | 0041-1132 1537-2995 |
language | eng |
recordid | cdi_proquest_miscellaneous_1464498669 |
source | Wiley |
subjects | Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antibodies, Monoclonal, Murine-Derived - administration & dosage Antigens, CD34 - metabolism Antineoplastic Combined Chemotherapy Protocols - administration & dosage Apheresis Biological and medical sciences Blood Component Removal - methods Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Bone marrow, stem cells transplantation. Graft versus host reaction Combined Modality Therapy Cyclophosphamide - administration & dosage Doxorubicin - administration & dosage Female Follow-Up Studies Granulocyte Colony-Stimulating Factor - administration & dosage Hematopoietic Stem Cell Mobilization - methods Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - metabolism Heterocyclic Compounds - administration & dosage Humans Leukocyte Count Lymphocyte Subsets - cytology Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - immunology Male Medical sciences Middle Aged Prednisone - administration & dosage Receptors, CXCR4 - antagonists & inhibitors Retrospective Studies Rituximab Stem Cell Transplantation Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation, Autologous Vincristine - administration & dosage |
title | Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20graft%20lymphocyte%20subsets%20after%20plerixafor%20injection%20in%20non-Hodgkin's%20lymphoma%20patients%20mobilizing%20poorly%20with%20chemotherapy%20plus%20granulocyte-colony-stimulating%20factor&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Varmavuo,%20Ville&rft.date=2012-08&rft.volume=52&rft.issue=8&rft.spage=1785&rft.epage=1791&rft.pages=1785-1791&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/j.1537-2995.2011.03525.x&rft_dat=%3Cproquest_cross%3E1464498669%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4705-33a115d1a505dbccbb750df610cf633dc4c74c55a3575386999a6e78fce277123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1464498669&rft_id=info:pmid/22304442&rfr_iscdi=true |